Giulio Cassanello, Esther Drill, Annie Qiu, Mark D. Ewalt, Paul Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Maria Lia Palomba, Andrew D. Zelenetz, Ahmet Dogan, Klaus J. Busam, Joachim Yahalom, Gilles Salles, Matthew J. Matasar, Lorenzo Falchi
{"title":"利妥昔单抗时代原发性皮肤型DLBCL患者的治疗结果和中枢神经系统复发风险","authors":"Giulio Cassanello, Esther Drill, Annie Qiu, Mark D. Ewalt, Paul Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Maria Lia Palomba, Andrew D. Zelenetz, Ahmet Dogan, Klaus J. Busam, Joachim Yahalom, Gilles Salles, Matthew J. Matasar, Lorenzo Falchi","doi":"10.1038/s41408-025-01354-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"52 1","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era\",\"authors\":\"Giulio Cassanello, Esther Drill, Annie Qiu, Mark D. Ewalt, Paul Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Maria Lia Palomba, Andrew D. Zelenetz, Ahmet Dogan, Klaus J. Busam, Joachim Yahalom, Gilles Salles, Matthew J. Matasar, Lorenzo Falchi\",\"doi\":\"10.1038/s41408-025-01354-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"52 1\",\"pages\":\"\"},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-025-01354-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-025-01354-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.